Categories LATEST, U.S. Markets News

After Buffett and Dimon, Trump pushes to end quarterly results

Earlier in June, two Wall Street veterans had lambasted the practice of announcing quarterly results, stating it would hinder the long-term goals of companies. Berkshire Hathaway (BRK.A) CEO Warren Buffett and JPMorgan Chase (JPM) chief Jamie Dimon also started an initiative, backed by a few other CEOs, to draft a document of voluntary governance guidelines that make quarterly announcements optional.

On Friday, investors were greeted by President Donald Trump’s tweet that said he has asked the Securities and Exchange Commission (SEC) to study the possibility of transitioning into half-yearly results, instead of quarterly results, for public companies.

Related: If Buffett has his way, quarterly guidance will soon become history

Trump said, following discussions with “business leaders,” he has come to the conclusion that a shift to half-yearly results would create more employment and enhance business performance.

While on one side such a move would make investment decisions cumbersome, on the other, it would take off the burden that companies have to meet the short-term targets set by analysts. Since stock movements are directly linked to the quarterly performance, executives are often tempted to operate against their long-term goals. Or as Dimon stated, quarterly earnings intrude into the management’s business strategy.

There is also an emerging trend where activist investors are putting pressure on companies to meet earnings expectations.

Investors unhappy

Meanwhile, many investors are irked by Trump’s move, stating that quarterly results are key to maintaining transparency and accountability in the trading environment. Many investors also expressed hope that the SEC would not give a green signal to such a shift.

Related: Donald Trump’s ultimate boycott list

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top